# Pulsed Radiofrequency to the Dorsal Root Ganglion in Postherpetic Neuralgia

Radiofrequenza pulsata al ganglio della radice dorsale

nella nevralgia posterpetica

## **Case report**

Pathos 2018, 25; 3. Online 2018, October 31



https://doi.org/10.30458/PA2018-189

## Antonino Genovese, Maria De Florio

Anaesthesia, Intensive Care and Pain Therapy Unit

ASP Messina, Patti, Italy

# Luigi Cardia, Giovanni De Salvo, Cristiana Giacoppo,

## Epifanio Mondello

Anaesthesia, Intensive Care and Pain Therapy Unit

Messina University, Italy

**Summary** Herpes Zoster is an infectious disease caused by the reactivation of the latent varicella-Zoster virus. Postherpetic neuralgia (PHN) is the most common complication of herpes Zoster and can impair the quality of life due to severe pain symptoms. Post-herpetic neuralgia is difficult to treat and over 50 percent of patients fail to achieve satisfactory pain relief. The authors present a clinical case involving a 74-year-old patient suffering from Post-herpetic neuralgia; this study reveals that dorsal root ganglion pulsed radiofrequency was effective in treating Post-herpetic neuralgia.

**Riassunto** L'Herpes Zoster è una malattia infettiva causata dalla riattivazione del virus latente della varicella-zoster. La nevralgia post-erpetica (PHN) è la complicanza più comune dell'herpes Zoster e può compromettere la qualità della vita a causa dei sintomi, soprattutto del dolore grave. La nevralgia post-erpetica è difficile da trattare e oltre il 50 per cento dei pazienti non riesce a ottenere un soddisfacente sollievo dal dolore. Gli autori presentano un caso clinico che riguarda un paziente di 74 anni affetto da questa malattia; lo studio rivela che la radiofrequenza pulsata del ganglio della radice dorsale è stata efficace nel trattamento della nevralgia post-erpetica.

Key words Herpes Zoster, Post-herpetic Neuralgia, Neuropathic Pain, Pulsed Radiofrequency, Dorsal Root Ganglion

**Parole chiave** Herpes Zoster, Nevralgia post-erpetica, Dolore neuropatico, Radiofrequenza pulsata, Ganglio della radice dorsale

## Introduction

Herpes Zoster is an infectious disease caused by the reactivation of latent varicella-zoster virus (VZV), with a lifetime

incidence of 30%.<sup>1</sup> Symptoms are non-specific and range from itching to an intense burning sensation.<sup>2</sup> The mechanisms of pain in the acute phase of herpes Zoster are not completely clarified.<sup>3,4</sup> Studies demonstrated that a combination of neuropathic and nociceptive pain is generated. The nociceptive component is caused by the skin inflammation that leads to excitement and sensitization of nociceptors.<sup>5</sup> Furthermore, an increased afferent activity transmitted to the spinal cord produces a central hyperexcitability state in the neurons of the posterior horn of the spinal cord, which decreases progressively in conjunction with the healing of tissue damage in the majority of patients. The neuropathic component is caused by direct damage caused by the virus and the inflammation in the dorsal root ganglion, in the peripheral nerve and in some cases also in the dorsal roots and spinal cord. The most common, and one of the most fearsome, complication of the infection is the post-herpetic neuralgia, whose incidence is directly related to aging.<sup>6-8</sup> Post-herpetic neuralgia often impairs patient's quality of life due to the related, and severe, painful symptoms.<sup>9,10</sup> Post-herpetic Neuralgia is defined as a pain distributed in the segment affected by the typical acute herpetic eruption, which persists after healing of the rash (usually one month after their onset). The incidence was estimated between 9 and 14 percent of

cases affected by the acute form.<sup>11,12</sup> Postherpetic Neuralgia is difficult to treat and over 50 percent of patients fail to achieve satisfactory pain relief, despite the application of the most effective methods of treatment available, including opioids.<sup>13</sup> Pulsed Radio Frequency is considered a safer strategy compared to the classic Radio Frequency treatment.<sup>14</sup> PRF act mainly, or exclusively, on the unmyelinated C fibers (this would explain their ability to provide pain relief without interfering with the motility and the sensitivity) or on myelinated A Delta and A Beta fibers.<sup>15</sup>

## **Case report**

A 74-year-old man with a herpetic infection lasting over ten months. It presents neuropathic pain diagnosed by a pain therapist and described using the Numerical Rating Scale (NRS) of 10 points, in the right subcostal region until reaching the navel region (Figure 1). The patient was initially treated with pregabalin (maximum dose of 75 mg, 3 times a day) and tapentadol (maximum dose of 300 mg, 2 times a day).<sup>16</sup> Furthermore, in association with the pharmacological therapy, a 5% lidocaine patch was applied in the topographical region of the rush. Initial therapy was not effective to treat pain, and, on the basis of the therapeutic failure of the initial pharmacological strategy, the patient underwent a cycle of 3 paravertebral blocks with Electrical Nerve Stimulation (ENS), performed using ultrasound guidance. This strategy was capable to obtain a partial reduction of the symptomatology for short periods (of 5 days maximum). To improve the positive effects obtained, the physicians decided to perform a PRF treatment (Figures 2 and 3) of the T12 and L1 ganglia (PRF 65V for 5 minutes). After this cycle, the patient reported partial pain relief, within the 48 hours following the treatment, which was followed by the resumption of pain symptoms. Thirty days after the PRF treatment, a reduction of 50% of the pain symptomatology (NRS 5) was shown during the algological follow-up examination. On this occasion the dosage of pregabalin (75 mg 1 time a day) and tapentadol (150 mg 2 times a day) was reduced. Sixty days after the execution of the PRF the pain was further reduced (NRS 3), and the pharmacological therapy was subsequently suspended. After 30 days the patient did not take any opioids, continue instead to take pregabalin 75 mg (1 time a day). Ninety days after the PRF, the pain remains tolerable (NRS 3), the patient reported a feeling of discomfort and rare "electric shocks" during sudden movements.

## Discussion

PRF of dorsal root ganglion (DRG) represents an innovative technique, in those cases where standard approaches are marginally effective.<sup>17,18</sup>

This procedure has a relatively lower impact on hemodynamics. Although the exact analgesic mechanism of PRF has not been fully elucidated, recent finding reported an increased c-fos expression,<sup>19,20</sup> that could be an evidence of small

Alpha, Delta and C fibers selective lesioning,<sup>21</sup> and increased synaptic transmission changes,<sup>22</sup> and this neural tissue modification may contribute to the long-term effects of PRF. Although further controlled prospective trials, with appropriate sample sizes, are needed to prove these findings.

# Conclusion

This study revealed that DRG-PRF was effective in treating pain symptoms of Post-herpetic Neuralgia.23,24 On the basis of our results, in cases with progressive neuropathic changes such as those following the acute stage of herpes Zoster, dorsal root ganglion pulsed radiofrequency treatment could represent an effective therapeutic option for pain symptoms of Post-herpetic Neuralgia.

# **Conflict of interest**

The authors certify the study was conducted without conflicts of interest.

# Published

31th October 2018

#### **Bibliografia**

1) Kinchington PR, Goins WF. Varicella zoster virus-induced pain and post-herpetic neuralgia in the human host and in rodent animal models. J Neurovirol 2011;17:590–599.

2) Johnson R, McElhaney J, Pedalino B, Levin M: Prevention of herpes zoster and its painful and debilitating complications. Int J Infect Dis 2007, 11(Suppl 2):S43-S48.

3) Watson CPN, Deck JH, Morshead C, Van der Kooy D, Evans RJ. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain1991;44:105-117.

4) Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol 1998;44:789-795.

5) Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiology Rev. 2013;26:728–43.

6) Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.

7) Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001;32(10):1481-6.6.

8) Morant-Talamante N, Diez-Domingo J, Martinez-Ubeda S, Puig-Barbera J, Aleman-Sanchez S, Perez-Breva L Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infect Dis 2013;13:463.

9) Schmidt-Ott R, Schutter U, Simon J, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study. J Infect. 2018 May;76(5):475-482. doi: 10.1016/j.jinf.2018.02.001. Epub 2018 Feb 8.

**10)** Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain 2004, 5:344-356.

11) Mick G, Hans G. Postherpetic neuralgia in Europe: the scale of the problem and outlook for the future. J Clin Geron Geriat. 2013;4:102–8.

12) Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster: the European view. Am J Clin Dermatol 2005;6:317-325.

13) Shrestha M, Chen A. Modalities in managing postherpetic neuralgia. Korean J Pain. 2018 Oct;31(4):235-243. doi: 10.3344/kjp.2018.31.4.235. Epub 2018 Oct 1.

14) Costa C, Sanalitro E. Pulsed radiofrequency (PRF) on the dorsal root ganglion. Pathos 2014; 21; 2. Online 2014, June 23.

15) Genovese A, Cardia L, Mondello E, et al. Pulsed radiofrequency in patients with chronic shoulder pain. Pathos 2016; 23; 3. https://doi.org/10.30458/PA2016-171.

16) Paolo Marchettini, Eliana Mauri, Claudio Marangoni. Gabapentin and Pregabalin in chronic neuropathic pain: cost efficacy evaluation. Pathos. 2005;12(1-2):22-26.

17) Kim ED, Lee YI, Park HJ. Comparison of efficacy of continuous epidural block and pulsed radiofrequency to the dorsal root ganglion for management of pain persisting beyond the acute phase of herpes zoster. PLoS One. 2017 Aug 21;12(8):e0183559. doi: 10.1371/journal.pone.0183559. eCollection 2017. PMID: 28827823.

**18)** Kim K, Jo D, Kim E. Pulsed Radiofrequency to the Dorsal Root Ganglion in Acute Herpes Zoster and Postherpetic Neuralgia. Pain Physician. 2017 Mar;20(3):E411-E418.

**19)** Haguichi Y, Nashold BS, Sluijter M, Cosman E, Pearlstein RD. Exposure of the dorsal root ganglion in rats to pulsed radiofrequency currents activities dorsal horn lamina I and II neurons. Neurosurgery 2002; 50: 850–855. PMID: 11904038.

20) Van Zundert J, de Louw AJ, Joosten EA, Kessels AG, Honig W, Dederen PJ, et al. Pulsed and continuous radiofrequency current adjacent to the cervical dorsal root ganglion of the rat induces late cellular activity in the dorsal horn. Anesthesiology 2005; 102:

125-131. PMID: 15618796.

21) Hamann W, Abou-Sherif S, Thompson S, Hall S.Pulsed radiofrequency applied to dorsal root ganglia causes a selective increase in ATF3 in small neurons. Eur J Pain 2006; 10:171–176. https://doi.org/10. 1016/j.ejpain.2005.03.001 PMID: 16310722.

22) Cahana A, Vutskits L, Muller D. Acute differential modulation of synaptic transmission and cell survival during exposure to pulsed and continuous radiofrequency energy. J Pain 2003; 4:197–202. PMID: 14622704.

23) Dong Wang et al. PainVision® Apparatus for Assessment of Efficacy of Pulsed Radiofrequency Combined with Pharmacological Therapy in the Treatment of Postherpetic Neuralgia and Correlations with Measurements. BioMed Research International. 2017; 2017 DOI 10.1155/2017/5670219.

24) Dan Li et al. Combined therapy of pulsed radiofrequency and nerve block in postherpetic neuralgia patients: a randomized clinical trial. PeerJ. 2018;6:e4852 DOI 10.7717/peerj.4852.